In this context, the primary objective of this work was to analyze the presence of EGFR mutations in cfDNA in plasma of 86 patients with lung cancer undergoing oncological treatment and to study their relationship with the response to treatment with TKIs. This evidence concerns the gene EGFR and lung carcinoma.